Mario Tumbarello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6950505/publications.pdf

Version: 2024-02-01

169 papers 11,268 citations

25034 57 h-index 100 g-index

173 all docs

173
docs citations

173 times ranked

10124 citing authors

#	Article	IF	CITATIONS
1	Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy. Clinical Infectious Diseases, 2012, 55, 943-950.	5.8	855
2	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
3	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Î ² -Lactamase-Producing <i>Enterobacteriaceae</i> Importance of Inadequate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2007, 51, 1987-1994.	3.2	382
4	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
5	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq1 1 0.	.7 8.4 314 r	gBIZ#Overl <mark>oc</mark>
6	Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. Journal of Clinical Microbiology, 2007, 45, 1843-1850.	3.9	300
7	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by ⟨i⟩Klebsiella pneumoniae ⟨ i⟩Carbapenemase–producing ⟨i⟩K. pneumoniae ⟨ i⟩. Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
8	Bloodstream Infections Caused by Extended-Spectrum- \hat{l}^2 -Lactamase-Producing <i>Klebsiella pneumoniae</i> : Risk Factors, Molecular Epidemiology, and Clinical Outcome. Antimicrobial Agents and Chemotherapy, 2006, 50, 498-504.	3.2	243
9	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Medicine, 2014, 40, 839-845.	8.2	209
10	In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. Journal of Infectious Diseases, 1999, 180, 448-453.	4.0	205
11	High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care, 2014, 18, R90.	5.8	192
12	Direct MALDI-TOF Mass Spectrometry Assay of Blood Culture Broths for Rapid Identification of Candida Species Causing Bloodstream Infections: an Observational Study in Two Large Microbiology Laboratories. Journal of Clinical Microbiology, 2012, 50, 176-179.	3.9	190
13	Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4085-4091.	3.2	185
14	Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. Journal of Clinical Microbiology, 2013, 51, 4167-4172.	3.9	176
15	Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. PLoS ONE, 2012, 7, e33705.	2.5	170
16	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine, 2013, 39, 2092-2106.	8.2	169
17	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	8.2	165
18	Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1â†'3)-β-D-glucan assay, Candida score, and colonization index. Critical Care, 2011, 15, R249.	5.8	152

#	Article	IF	CITATIONS
19	Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria. Chest, 2013, 144, 1768-1775.	0.8	150
20	Incidence and clinical impact of extended-spectrum-l ² -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. Journal of Infection, 2009, 58, 299-307.	3.3	144
21	Identifying Patients Harboring Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. Antimicrobial Agents and Chemotherapy, 2011, 55, 3485-3490.	3.2	137
22	Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Medicine, 2013, 39, 682-692.	8.2	137
23	A Multinational, Preregistered Cohort Study of \hat{l}^2 -Lactam/ \hat{l}^2 -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
24	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Medicine, 2015, 41, 776-795.	8.2	133
25	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing ⟨i⟩K. pneumoniae⟨ i⟩ Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
26	Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 20-25.	2.1	126
27	Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer. Current Opinion in Infectious Diseases, 2014, 27, 200-210.	3.1	125
28	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
29	Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. International Journal of Antimicrobial Agents, 2019, 53, 408-415.	2.5	120
30	Bloodstream infections caused by ⟨i⟩Klebsiella pneumoniae⟨ i⟩ in oncoâ€hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. American Journal of Hematology, 2016, 91, 1076-1081.	4.1	115
31	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagnostic Microbiology and Infectious Disease, 2007, 58, 325-331.	1.8	104
32	Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase- Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy, 2008, 52, 3244-3252.	3.2	104
33	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320.	4.4	100
34	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 2017, 31, 17-29.	5.7	98
35	Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence, 2017, 8, 470-484.	4.4	97
36	Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2014, 58, 851-858.	3.2	91

#	Article	IF	CITATIONS
37	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
38	Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagnostic Microbiology and Infectious Disease, 2009, 64, 320-326.	1.8	82
39	Predictors of mortality in multidrug-resistant <i>Klebsiella pneumoniae</i> bloodstream infections. Expert Review of Anti-Infective Therapy, 2013, 11, 1053-1063.	4.4	82
40	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. Journal of Chemotherapy, 2017, 29, 197-214.	1.5	81
41	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitution–Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virus–Infected Subjects. Journal of Infectious Diseases, 2002, 185, 188-195.	4.0	79
42	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. Clinical Infectious Diseases, 2012, 55, 1515-1521.	5.8	77
43	Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology. Emerging Infectious Diseases, 2002, 8, 220-221.	4.3	75
44	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	75
45	$(1,3)$ - \hat{l}^2 -d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2262-2269.	3.0	73
46	ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. Journal of Antimicrobial Chemotherapy, 2004, 53, 277-282.	3.0	68
47	Antifungal Susceptibility Profiles of Bloodstream Yeast Isolates by Sensititre YeastOne over Nine Years at a Large Italian Teaching Hospital. Antimicrobial Agents and Chemotherapy, 2015, 59, 3944-3955.	3.2	68
48	Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica, 2011, 96, e1-e3.	3.5	67
49	In Vitro Activities of Anidulafungin and Other Antifungal Agents against Biofilms Formed by Clinical Isolates of Different Candida and Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2011, 55, 3031-3035.	3.2	67
50	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	3.3	67
51	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLoS ONE, 2017, 12, e0170236.	2.5	67
52	Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2002, 50, 375-382.	3.0	66
53	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy. BMC Infectious Diseases, 2004, 4, 46.	2.9	65
54	Combined use of serum $(1,3)$ - \hat{l}^2 -d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Critical Care, 2017, 21, 176.	5.8	65

#	Article	IF	CITATIONS
55	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	3.5	64
56	T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood. Journal of Antimicrobial Chemotherapy, 2018, 73, iv20-iv26.	3.0	64
57	Meropenem/vaborbactam: a next generation \hat{l}^2 -lactam \hat{l}^2 -lactamase inhibitor combination. Expert Review of Anti-Infective Therapy, 2020, 18, 643-655.	4.4	64
58	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre studyâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	3.0	60
59	Molecular Mechanisms, Epidemiology, and Clinical Importance of \hat{I}^2 -Lactam Resistance in Enterobacteriaceae. International Journal of Molecular Sciences, 2020, 21, 5090.	4.1	60
60	Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. Journal of Clinical Microbiology, 2006, 44, 3257-3262.	3.9	57
61	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica, 2011, 96, 1366-1370.	3.5	56
62	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Journal of Antimicrobial Chemotherapy, 1996, 38, 691-699.	3.0	55
63	Older HIV-positive patients in the era of highly active antiretroviral therapy. Aids, 2003, 17, 128-131.	2.2	55
64	Detecting risk and predicting patient mortality in patients with extended-spectrum \hat{l}^2 -lactamase-producing <i>Enterobacteriaceae</i> bloodstream infections. Future Microbiology, 2012, 7, 1173-1189.	2.0	55
65	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
66	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	54
67	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. Aids, 2003, 17, 765-768.	2.2	54
68	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cellular Immunology, 1988, 115, 57-65.	3.0	52
69	Multidrug-Resistant Proteus mirabilis Bloodstream Infections: Risk Factors and Outcomes. Antimicrobial Agents and Chemotherapy, 2012, 56, 3224-3231.	3.2	51
70	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
71	Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. Journal of Antimicrobial Chemotherapy, 2008, 62, 1379-1385.	3.0	50
72	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infectious Diseases, 2020, 7, ofaa139.	0.9	49

#	Article	IF	Citations
73	Glycopeptide Resistance among Coagulaseâ€Negative Staphylococci that Cause Bacteremia: Epidemiological and Clinical Findings from a Caseâ€Control Study. Clinical Infectious Diseases, 2001, 33, 1628-1635.	5.8	48
74	Carbapenemase-producingKlebsiella pneumoniaeand Hematologic Malignancies. Emerging Infectious Diseases, 2014, 20, 1235-1236.	4.3	48
75	Performance of Two Resin-Containing Blood Culture Media in Detection of Bloodstream Infections and in Direct Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS) Broth Assays for Isolate Identification: Clinical Comparison of the BacT/Alert Plus and Bactec Plus Systems, Journal of Clinical Microbiology, 2014, 52, 3558-3567.	3.9	48
76	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardshipâ€"results from an international cross-sectional survey. World Journal of Emergency Surgery, 2017, 12, 34.	5.0	47
77	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- $\langle b \rangle$ 1 ² $\langle b \rangle$ -lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
78	Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. Open Forum Infectious Diseases, 2017, 4, ofx063.	0.9	44
79	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
80	Synthetic Peptides Corresponding to Sequences in HIV Envelope gp41 and gp120 Enhance <i>i</i> In Vitro l Production of Interleukin-1 and Tumor Necrosis Factor but Depress Production of Interferon- l and Interferon- l and Interleukin-2. Viral Immunology, 1991, 4, 33-42.	1.3	41
81	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
82	Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. Critical Care, 2021, 25, 197.	5.8	41
83	Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. Current Opinion in Infectious Diseases, 2018, 31, 566-577.	3.1	40
84	Evaluation of the New NucliSENS EasyQ KPC Test for Rapid Detection of Klebsiella pneumoniae Carbapenemase Genes (<i>bla</i> _{KPC}). Journal of Clinical Microbiology, 2012, 50, 2783-2785.	3.9	38
85	Mortality in patients with early- or late-onset candidaemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 927-935.	3.0	37
86	Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Medicine, 2015, 41, 103-110.	8.2	37
87	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Annals of Intensive Care, 2020, 10, 94.	4.6	36
88	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal of Antimicrobial Association 2023, 60, 106611	2.5	36
89	of Antimicrobial Agents, 2022, 60, 106611. Osteoarticular bacterial infections are rare in HIV-infected patients: 14 cases found among 4, 023 HIV-infected patients. Acta Orthopaedica, 1997, 68, 554-558.	1.4	35
90	Severe pneumonia in intensive care. Current Opinion in Pulmonary Medicine, 2012, 18, 213-221.	2.6	34

#	Article	IF	CITATIONS
91	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
92	Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Research and Therapy, 2006, 3, 22.	1.7	33
93	Nosocomial Bloodstream Infections in HIV-Infected Patients: Attributable Mortality and Extension of Hospital Stay. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 490-497.	0.3	32
94	Fungal infections in the ICU. Current Opinion in Critical Care, 2015, 21, 421-429.	3.2	32
95	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
96	New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics, 2022, 11, 579.	3.7	31
97	$(1,3)$ - \hat{l}^2 -d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. Critical Care, 2020, 24, 550.	5.8	30
98	Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. European Journal of Cardio-thoracic Surgery, 2017, 52, 768-774.	1.4	29
99	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	2.2	29
100	Azole Resistance of Candida glabrata in a Case of Recurrent Fungemia. Journal of Clinical Microbiology, 2006, 44, 3046-3047.	3.9	27
101	Etiology of Febrile Episodes in Patients With Acute Myeloid Leukemia: Results From the Hema e-Chart Registry. Archives of Internal Medicine, 2011, 171, 1502.	3.8	27
102	Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS ONE, 2019, 14, e0224465.	2.5	27
103	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. European Journal of Gastroenterology and Hepatology, 1997, 9, 307-310.	1.6	26
104	Safety and Effectiveness of Transvenous Lead Extraction in Octogenarians. Journal of Cardiovascular Electrophysiology, 2012, 23, 1103-1108.	1.7	25
105	Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Review of Anti-Infective Therapy, 2006, 4, 875-885.	4.4	22
106	Highly Active Antiretroviral Therapy Decreases the Incidence of Bacteremia in Human Immunodeficiency Virusâ€Infected Individuals. Clinical Infectious Diseases, 1998, 27, 901-902.	5.8	21
107	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. Journal of Antimicrobial Chemotherapy, 2014, 69, 3142-3147.	3.0	21
108	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance, 2020, Volume 13, 4697-4711.	2.7	21

#	Article	IF	Citations
109	HIV-Associated Bacterial Pneumonia in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 208-209.	0.3	20
110	Fungaemia in haematological malignancies: SEIFEMâ€2015 survey. European Journal of Clinical Investigation, 2019, 49, e13083.	3.4	20
111	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. Aids, 2000, 14, 2948-2949.	2.2	20
112	Relapsing bloodstream infections during treatment of acute leukemia. Annals of Hematology, 2014, 93, 785-790.	1.8	19
113	Oral Lichenoid Lesions in HIV-HCV-Coinfected Subjects During Antiviral Therapy: 2 Cases and Review of the Literature. American Journal of Dermatopathology, 2008, 30, 466-471.	0.6	18
114	Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Review of Anti-Infective Therapy, 2011, 9, 1067-1075.	4.4	18
115	Predictors of Mortality with Staphylococcus aureus Bacteremia in Elderly Adults. Journal of the American Geriatrics Society, 2018, 66, 1284-1289.	2.6	18
116	Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. Journal of Critical Care, 2019, 50, 169-176.	2.2	18
117	Derivation and Validation of a Scoring System to Identify Patients with Bacteremia and Hematological Malignancies at Higher Risk for Mortality. PLoS ONE, 2012, 7, e51612.	2.5	18
118	Azole Susceptibility Patterns and Genetic Relationship Among Oral Candida Strains Isolated in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 38-44.	2.1	17
119	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica, 2017, 102, e407-e410.	3.5	17
120	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	4.7	17
121	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. JAC-Antimicrobial Resistance, 2022, 4, dlac022.	2.1	17
122	Primary central nervous system lymphoma and brain biopsy in AIDS. Lancet, The, 1993, 341, 1411-1412.	13.7	15
123	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	15
124	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <scp>SEIFEM</scp> â€D registry. British Journal of Haematology, 2015, 170, 434-439.	2.5	14
125	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. Journal of Chemotherapy, 2019, 31, 9-14.	1.5	14
126	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13

#	Article	IF	CITATIONS
127	High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis Caused by Staphylococcal Small-Colony Variants. Clinical Infectious Diseases, 2012, 54, 1516-1517.	5.8	12
128	Antibodies against a \hat{l}^2 -glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. Scientific Reports, 2017, 7, 2722.	3.3	12
129	Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 413-417.	2.9	12
130	Oirect use of eazyplex [®] SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections. Infection and Drug Resistance, 2019, Volume 12, 1055-1062.	2.7	11
131	The role of carbapenem-resistant pathogens in cSSTI and how to manage them. Current Opinion in Infectious Diseases, 2019, 32, 113-122.	3.1	11
132	â€~Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1062-1068.	3.0	11
133	Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. International Journal of Antimicrobial Agents, 2020, 55, 105900.	2.5	11
134	Invasive Respiratory Fungal Infections in COVID-19 Critically III Patients. Journal of Fungi (Basel,) Tj ETQq0 0 0 rg	BT <u> O</u> verlo	ck 10 Tf 50 4
135	Oral lesions in HIV and HCV coâ€infected individuals in HAART era. Journal of Oral Pathology and Medicine, 2008, 37, 468-474.	2.7	10
136	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). Annals of Hematology, 2018, 97, 791-798.	1.8	10
137	Efficacy of βâ€lactam/βâ€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing <i>Enterobacterales</i> bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€SOT Project). Transplant Infectious Disease, 2021, 23, e13520.	1.7	10
138	Age as a prognostic factor in AIDS. Lancet, The, 1996, 348, 623-624.	13.7	9
139	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. Critical Care, 2016, 20, 246.	5.8	9
140	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. Blood, 2014, 124, 3880-3880.	1.4	9
141	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	2.2	8
142	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
143	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunology Letters, 1995, 47, 223-226.	2.5	7
144	Why Should We Monitor $(1-3)$ - \hat{l}^2 - $\langle scp \rangle d \langle scp \rangle$ -Glucan Levels during Invasive Candidiasis? Just Ask Your Ophthalmologist!. Journal of Clinical Microbiology, 2013, 51, 1645-1646.	3.9	7

#	Article	IF	Citations
145	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.9	7
146	Comment on: Mortality due to <i>bla</i> _{KPC} <i>Klebsiella pneumoniae</i> bacteraemia. Journal of Antimicrobial Chemotherapy, 2016, 71, 1743.1-1744.	3.0	6
147	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. Leukemia and Lymphoma, 2017, 58, 2859-2864.	1.3	6
148	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Î ² -Lactamase-Producing <i>Enterobacteriaceae</i> Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2007, 51, 3469-3469.	3.2	5
149	Fluconazole Use as an Important Risk Factor in the Emergence of Fluconazole-Resistant Candida glabrata Fungemia. Archives of Internal Medicine, 2009, 169, 1444.	3.8	5
150	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Critical Reviews in Oncology/Hematology, 2021, 158, 103203.	4.4	4
151	Neurological involvement during legionellosis, look beyond the lung. Journal of Neurology, 2012, 259, 2243-2245.	3.6	3
152	Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?. Intensive Care Medicine, 2018, 44, 1982-1984.	8.2	3
153	Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. Blood, 2015, 126, 3757-3757.	1.4	3
154	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: a SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respiratory Medicine, 2021, 190, 106674.	2.9	3
155	XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?. Antibiotics, 2022, 11, 193.	3.7	3
156	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. Journal of Chemotherapy, 2022, 34, 524-533.	1.5	3
157	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. Aids, 2004, 18, 1602-1604.	2.2	2
158	Reply to "ldentifying Patients Harboring Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae on Hospital Admission Is Not That Simple― Antimicrobial Agents and Chemotherapy, 2012, 56, 2220-2220.	3.2	1
159	Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients. Journal of Chemotherapy, 2015, 27, 250-252.	1.5	1
160	Reply to Wong et al. Clinical Infectious Diseases, 2015, 61, 1352-1352.	5.8	1
161	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	1.4	1
162	Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. Antibiotics, 2021, 10, 1554.	3.7	1

#	Article	IF	CITATIONS
163	A national voice for information about HIV infections: The Italian state AIDS hot-line. Public Health, 1989, 103, 447-454.	2.9	0
164	Esthesioneuroblastoma in an HIV-1 Infected Patient: Case Report. Skull Base Reports, 2011, 1, 129-132.	0.0	0
165	Response. Chest, 2014, 145, 927-928.	0.8	O
166	The current role of glycopeptides in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	1.5	0
167	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. Blood, 2014, 124, 3682-3682.	1.4	0
168	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	1.4	0
169	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. Blood, 2016, 128, 3700-3700.	1.4	0